Terns Pharmaceuticals Inc - Asset Resilience Ratio
Terns Pharmaceuticals Inc (TERN) has an Asset Resilience Ratio of 48.05% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Terns Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Terns Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Terns Pharmaceuticals Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Terns Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TERN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $144.94 Million | 48.05% |
| Total Liquid Assets | $144.94 Million | 48.05% |
Asset Resilience Insights
- Very High Liquidity: Terns Pharmaceuticals Inc maintains exceptional liquid asset reserves at 48.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Terns Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Terns Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Terns Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.06% | $196.72 Million | $363.93 Million | -14.29pp |
| 2023-12-31 | 68.34% | $183.51 Million | $268.52 Million | +19.61pp |
| 2022-12-31 | 48.73% | $139.88 Million | $287.03 Million | -21.64pp |
| 2021-12-31 | 70.38% | $118.28 Million | $168.07 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $92.29 Million | -- |
| 2019-12-31 | 30.64% | $7.32 Million | $23.90 Million | +25.74pp |
| 2018-12-31 | 4.90% | $4.36 Million | $89.07 Million | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more